DPP4 and bacterial urinary tract infection: Finally, Alkabbani et al. showed, in a large population-based cohort study, that SGLT-2 inhibitors were not associated with a higher risk of UTI than DPP-4 inhibitors, GLP-1 RA, or tiazolidindiones; however, the risk of UTI was lower when compared with insulin treatment [59].